02243nas a2200265   4500000000100000008004100001260001200042653001200054653001500066653001400081653001700095653001200112100001200124700001400136700001400150700001400164700001300178700001200191245009900203856026000302300001400562490000700576520136900583022002501952       2024                            d  bMedknow10aDapsone10ahaemolysis10aTreatment10aRisk Factors10aLeprosy1 aNaik KP1 aGanguly S1 aShukla AK1 aChhabra N1 aPrabha N1 aAhmed G00aDapsone-induced haemolysis among leprosy patients on MDT from an endemic area of central India  uhttps://www.researchgate.net/profile/Namrata-Chhabra/publication/383931893_Dapsone-induced_haemolysis_among_leprosy_patients_on_MDT_from_an_endemic_area_of_central_India/links/66e26ba8f84dd1716ce77dd6/Dapsone-induced-haemolysis-among-leprosy-patients-on-M  a3887-38910 v133 a<p><strong>Background and Aim:</strong> Haemolysis due to dapsone as a part of MDT in leprosy patients has been long recognized. However, the frequency and severity of this side effect and factors associated with it have not been well documented. We planned to determine the frequency of dapsone-induced haemolysis in leprosy patients on MDT and various risk factors associated with it.</p>

<p><strong>Materials and Methods: </strong>This was a hospital-based retrospective analysis, conducted on 36 treatment completed or partially treated or on treatment leprosy patients in a tertiary care centre in Chhattisgarh.</p>

<p><strong>Results: </strong>Out of 36 patients, 83.3% showed a fall in haemoglobin from the baseline value (pre-treatment values). Dapsone was stopped in 33.3% of patients with a significant fall in haemoglobin. We found that the mean haemoglobin concentration for all patients fell from 13.05(+/−1.8) g/dl to 11.8(+/−1.9) g/dl (P &lt; 0.05) which was statistically significant. A total of 25% of patients were labelled as confirmed cases of dapsone-induced haemolysis as per our definition.</p>

<p><strong>Conclusion:</strong> Our results underline the need to incorporate haematological investigations in leprosy management protocol, especially in primary care settings where the majority of leprosy patients are managed.</p>
  a2249-4863, 2278-7135